Results 241 to 250 of about 88,672,115 (295)

LAG-3 : recent developments in combinational therapies in cancer. [PDF]

Cancer Sci
Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, Garrido C.   +4 more
europepmc   +1 more source

PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer. [PDF]

Front Immunol
Wu Y, Chen C, Cui Y, Zou R, Yang Y, Sun F, Du Y, Wang P.   +7 more
europepmc   +1 more source

The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming. [PDF]

Sci Transl Med
Rolig AS, Peng X, Sturgill ER, Holay N, Kasiewicz M, Mick C, Mcgee GH, Miller W, Koguchi Y, Kaufmann J, Yanamandra N, Griffin S, Smothers J, Adamow M, Lee J, Shen R, Callahan MK, Redmond WL.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

LAG-3 as the third checkpoint inhibitor

Nature Immunology, 2023
Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more than 20 LAG-3-targeting therapeutics in clinical trials and a fixed-dose combination of anti-LAG-3 and anti-PD-1 now approved to treat unresectable or metastatic melanoma.
Vaishali Aggarwal, Creg J. Workman, Dario A. A. Vignali   +2 more
openaire   +2 more sources

Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy

Clinical Cancer Research, 2022
Summary Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti–PD-(L)1 in the IFNγ associated T-cell–inflamed tumor microenvironment. The bispecific lymphocyte activation gene 3 (LAG-3) and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve ...
Lilit Karapetyan, Jason J. Luke
openaire   +2 more sources

LAG-3: a very singular immune checkpoint

Nature Immunology, 2018
The mechanism of action of the lymphocyte checkpoint protein LAG-3 was always rather mysterious. It now seems to operate at least in part by recognizing and suppressing responses to stable complexes of peptide and major histocompatibility complex class II.
Lui, Y, Davis, S
openaire   +3 more sources

Smoking Cessation Support Lags Behind Lung Cancer Screenings

Ca-A Cancer Journal for Clinicians, 2022
Mike Fillon
exaly  

Binding of LAG-3 to Stable Peptide-MHC Class II Limits T Cell Function and Suppresses Autoimmunity and Anti-Cancer Immunity

Immunity, 2022
Il-Mi Okazaki, Daisuke Sugiura, Takeo Meda   +2 more
exaly  

LAG-3 Role in Neurological Diseases

Proceedings of MOL2NET'22, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 8th ed. - MOL2NET: FROM MOLECULES TO NETWORKS, 2022
Luisa Chocarro, Ester Blanco, Hugo Arasanz, Leticia Fernández Rubio, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Piñeiro, Grazyna Kochan, David Escors   +9 more
openaire   +1 more source